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The Ewing sarcoma family of tumors (ESFT) represents an aggressive spectrum of malignant tumour types with common deﬁning
histological and cytogenetic features. To evaluate the functional activation of signal transducer and activator of transcription 3
(STAT3) in ESFT, we evaluated its activation in primary tissue sections and observed the functional consequences of its inhibition
in ESFT cell lines. STAT3 was activated (tyrosine 705-phosphorylated) in 18 out of 31 primary tumours (58%), either diﬀusely
(35%) or focally (23%). STAT3 was constitutively activated in 3 out of 3 ESFT cell lines tested, and its speciﬁc chemical inhibition
resulted in complete loss of cell viability. STAT3 inhibition in ESFT cell lines was associated with several consistent changes in
chemokine proﬁle suggesting a role of STAT3 in ESFT in both cell survival and modiﬁcation of the cellular immune environment.
Together these data support the investigation of STAT3 inhibitors for the Ewing family of tumors.
1.Introduction
The Ewing sarcoma family of tumors (ESFT) is an aggressive
malignancy of childhood comprising a spectrum of tumour
types with common deﬁning histological and cytogenetic
features [1]. Overall mortality remains at around 40% de-
spite the introduction of multimodality therapy, and current
treatment protocols often cause signiﬁcant long-term mor-
bidity amongst survivors [2, 3]. The prognosis of ESFT is
unlikelytochangefundamentally,unlessnovelbiologicaltar-
gets for treatment are identiﬁed. One interesting potential
approach is to target the pathways that activate the transcrip-
tion factor STAT3, which acts as a point of convergence of
many diﬀerent oncogenic signals [4, 5]. In particular, STAT3
hasbeenshowntointegratepathwayswhichregulatetumour
growth and the immune microenvironment [6–8] and it is
known to be deregulated in a range of adult cancer types [9–
11]. However, the role of STAT3 in malignancies of child-
hood is poorly understood. Lai et al. demonstrated activated
STAT3 (i.e., STAT3 phosphorylated at the tyrosine 705 res-
idue) in approximately 50% of cases in a series of 49 ESFT
tumours by immunohistochemistry [12]. In this study we
sought to conﬁrm their ﬁndings and investigate in vitro
whether STAT3 integrates control of proliferation and the
tumour microenvironment in ESFT tumors.
2.MaterialsandMethods
2.1. Tissue Arrays. Paraﬃn-embedded tumor samples were
randomly selected from hospital histology archived material.
Haematoxylin and eosin stained sections were examined to
i d e n t i f ya r e a so fv i a b l et u m o u r .T i s s u ec o r e sw e r et a k e nf r o m
these areas using a skin biopsy punch (diameter 4mm) and
reembedded to produce 3 tissue arrays, comprising a total of
31 tumour cores.
2.2. Immunohistochemical Analysis. Immunohistochemical
analysis was performed on 4μm-thick sections, as previously
described [13]. As primary antibody, the phosphorylated
STAT3 (P-STAT3) monoclonal antibody clone 3E2 (Cell Sig-
nalling Technology, Boston, USA) was used at a dilution of2 Sarcoma
1:30. As positive control, tonsillar tissue was used. As nega-
tive control, the primary antibody was omitted. Analysis was
performed by two authors, initially independently and then
together to form a consensus opinion. The staining pattern
was assessed qualitatively and also semiquantitatively using
the following scoring system: 0, no reactivity; 1+, 1% to 10%
positive cells; 2+, 10% to 50% positive cells; 3+, more than
50% positive cells.
2.3. Cell Culture and Formalin Fixation. T h eE S F Tc e l ll i n e s
A673 and TC32 were kind donations of Professor Sue Burch-
ill, University of Leeds, UK. The ESFT cell line SKNMC, the
prostate cancer cell line PC3, and HeLa were obtained from
ATCC. Cell lines were maintained in the following media
by Gibco/Invitrogen (Pasley, UK): DMEM (cell lines A673,
SKNMC, HeLa), RPMI (cell line TC32), or F12 (cell line
PC3) media containing 10% foetal calf serum. For ﬁxing of
20ng/mL IL-6-treated HeLa cells (E-Bioscience), super-
natant was aspirated after 10 minutes activation, and cell
pelletswereﬁxedin10%formaldehydefor10minutesbefore
undergoing processing as for routine histopathology speci-
mens. Following processing, each sample was embedded in
paraﬃn.
2.4. Western Blotting. For production of lysates the following
experimental protocol was followed for ESFT and the PC3
cell lines. 500,000 cells were incubated in 2mL media for 16
hours. Media was then removed and replaced by 1mL of
fresh media in the presence or absence of the pharmacologi-
cal STAT3 inhibitor, S3i-201 (Calbiochem, Darmstadt, Ger-
many), at a concentration of 100μmol/L. 24 hours later the
c e l l sw e r eh a r v e s t e da n dl y s e du s i n gR I P Ab u ﬀer (Pierce
Biotechnology, Rockford, USA) containing protease inhibi-
torcocktail(PierceBiotechnology,Rockford,USA)andsodi-
um orthovanadate (Sigma-Aldrich, St. Louis, USA). West-
ern blotting was then performed on equal amounts (in
weight) of lysate as previously described [5], substituting the
milk-containing blocking solution with 10% bovine serum
albumin. The following primary antibodies were used with
overnight incubations: P-STAT3 (clone 9131, 1:500 solu-
tion) and STAT3 (clone 79D7, 1:2000 solution), both from
Cell Signalling Technology (Boston, USA), GADPH (1:2000
solution of clone G9545, Sigma-Aldrich, St. Louis, USA). As
positive controlforP-STAT3,lysatesofIL-6-stimulatedHeLa
cellswereused.AspositivecontrolforSTAT3,lysatesofHeLa
cells cultured in the presence of 0% foetal calf serum were
used.
2.5. Cell Viability Growth Assay. 25,000 cells were plated in
96-well ﬂat-bottom plates suspended in 100μL of media. 16
hours later, treatment was added. Each treatment condition
was performed in triplicates. 24 hours later, cell viability was
assessed, using 20μL of the CellTiter 96 Aqueous nonradio-
active cell proliferation assay based on the tetrazolium com-
pound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt, MTS
(Promega, Madison, USA). Absorbance was measured using
the 96-well plate BIO-RAD Model 680 microplate reader
(Hercules, USA).
2.6. Chemokine Arrays and Array Analysis. Supernatants for
chemokine array analysis were produced by following the
experimental protocol for production of lysates, as outlined
above. Before harvesting and lysing cells, spent media was
removed and stored at −80◦C, after centrifugation to remove
debris. The supernatants were analysed at a later stage using
theRayBiotech(Norcross,USA)HumanChemokineArray1
according to the manufacturer’s instructions, using over-
night incubations. The spots on the developed ﬁlms were
scanned with a BIO-RAD GS-800 Calibrated Densitometer
(Hercules, USA) and quantiﬁed using ImageQuant software
(GE Healthcare, Little Chalfont, UK). From each spot that
represented a chemokine, the background (negative control
spots) was subtracted. The chemokine spots were then nor-
malised against positive control spots. The values that were
obtained thus were density values expressed as percentage of
positive control spots. Further analysis was then carried out
using Microsoft Excel 2007 (Redmond, USA). Chemokines
which had changed in control experiments (PC3 cell line)
by more than 10% were excluded from further analysis, to
exclude potential oﬀ-target eﬀects. A change in chemokine
level was arbitrarily deﬁned as an increase or decrease by
more than 10%, observed in arrays from two independent
experiments.
3. Results
3.1. ESFT Are Characterised by a High Incidence of STAT3
Activation and Associated with Discrete Tissue Distribution
Patterns. Previous work has described a high incidence of
S T A T 3a c t i v a t i o ni nE S F T[ 12], and we were interested in
conﬁrming this ﬁnding in an independent tissue set, as well
as analysing tissue distribution of activated STAT3 within the
tumor microenvironment. As a marker of STAT3 activation,
we made use of a monoclonal antibody with speciﬁcity for
the tyrosine705-phosphorylated form of STAT3 (P-STAT3)
and ﬁrst validated its speciﬁcity using IL-6-treated or -
untreated HeLa cells (Figure 1(a)). We next stained a total
of 31 ESFT primary tumors and found that 18 cores (58%)
contained P-STAT3 positive tumour cells. Amongst these
positivesamplesweidentiﬁed2distinctdistributionpatterns
of P-STAT3 staining (Figure 1(b)). Positive cells were either
scattered throughout the tumor with no recognisable pattern
(termeddiﬀusestainingn = 11;35%),ortheyexistedinpos-
itively staining clusters (termed focal staining n = 7; 23%),
particularly along ﬁbrovascular bundles. The extent of P-
STAT3positivetumorcellsamongstdiﬀuselypositivetumors
wasgradedasfollows:8tumors1+;2tumors2+;1tumor3+.
3.2.Phosphorylated STAT3IsPresentinEwing’sCell Lines,But
Not PC3, Can Be Diminished by a STAT3 Inhibitor, and Re-
duces Viability in ESFT Cell Lines. We assessed the role of
P-STAT3 in contributing to tumour growth by performing
in vitro cell viability growth assays in a panel of ESFT cell
lines and in the STAT3-null prostate cancer cell line, PC3.Sarcoma 3
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Figure 1: PSTAT3 staining identiﬁes two distinct distribution patterns of PSTAT3 tumour cells in ESFT specimens. (a) Hela cells were
culturedinthepresenceorabsenceofIL-6priortoformationofcellpelletsforgeneratinglysateorembeddinginparaﬃnfollowingformalin
ﬁxation. A phospho-STAT3-speciﬁc antibody was used to probe lysates by Western blot or to stain cells by immunohistochemistry, magni-
ﬁcation ×200. (b) Representative staining patterns of primary ESFT samples. In the left panel, tumor cells are P-STAT3 negative whereas
endothelial cells stained positive for PSTAT3 (acting as an internal positive control, black arrows), magniﬁcation ×200.
ThepresenceorabsenceofP-STAT3inthecelllineswasdem-
onstratedbyWesternblottingaswastheabilityofthespeciﬁc
STAT3 inhibitor, S3i-201 [14], to abolish phosphorylation of
STAT3 (Figure 2(a)). Representative results of independent
cell growth assays (at least three per cell line) are shown in
Figure 2(b). Pharmacological inhibition of P-STAT3 by S3i-
201 for 24 hours resulted in reduced tumour proliferation
at a concentration of 100μmol/L in ESFT cell lines, but not
in the STAT3-negative PC3 cell line. S3i-201 treatment non-
speciﬁcally inhibited viability in growth conditions in all cell
lines (including the STAT3 negative PC3 cell line) at concen-
trations of 300μmol/L and 1000μmol/L, respectively.
3.3. STAT3 Inhibition in ESFT Cells Alters the Levels of a Lim-
ited Number of Chemokines. We next studied the eﬀects of
STAT3 inhibition on chemokine secretion patterns of ESFT
celllinesandoftheSTAT3-negativePC3cellline.Chemokine
arrays were performed on supernatants obtained from cells
cultured in the presence or absence of pharmacological
P-STAT3 inhibition. For each cell line, two independent
experiments were performed. Prior to analysis by chemokine
arrays, we conﬁrmed by Western blotting that P-STAT3 had
been blocked in the cells from which the supernatants had
been harvested (data not shown). Known STAT3-regulated
chemokines(e.g.,IL-8[15])wereaﬀectedbyP-STAT3inhibi-
tion in all ESFT cell lines, but not in the STAT3-negative PC3
cell line. In addition to this, each ESFT cell line exhibited
a distinct pattern of changes in chemokine levels shown in
Figure 3.
4. Discussion
We sought to conﬁrm that STAT3 is present in a subset of
ESFT tumours and to investigate the role of STAT3 in ESFT.
We were particularly interested in the role of STAT3 in con-
tributing to tumour growth and immune regulation, which
are classical roles described for STAT3 in adult tumours.
In our series, we demonstrated P-STAT3 positive tumour
cellsin 18/31 ESFTcores. In comparison, Lai et al. previously
found P-STAT3 positive tumour cells in 25 out of 49 tumour4 Sarcoma
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Figure 2: Phosphorylated STAT3 is present in Ewing’s cell lines, but not PC3, which can be diminished by S3i-201 and reduces viability in
ESFT cell lines. (a) Western blot analysis; Lysates from IL-6-stimulated and -unstimulated HeLa cells served as positive controls for P-STAT3
andtotalSTAT3,respectively.TheGADPHbandisrepresentativeofloadingineachlane.Dataarerepresentativeofatleastthreeindependent
experiments per cell line. (b) Cell viability is determined by MTT assay. Data are representative of at least three independent experiments
per cell line.
cores [4]. A particular strength and distinguishing feature of
our tissue arrays is the relatively large surface area of individ-
ual tissue cores (4mm diameter), which allows us to assess
tumour architecture. We made the observation that P-STAT3
positive cells were distributed in two distinct patterns, which
we termed diﬀuse and focal. Although we are unable to com-
ment on the signiﬁcance of this observation, the level of
organisation seen in the focal distribution pattern is intrigu-
ing. Given that around half of ESFT samples contained ac-
tivated STAT3 tumour cells, we continued to investigate the
role of STAT3 in ESFT in vitro.
We studied whether STAT3 contributes to tumour
growth by performing viability assays of cells in growth con-
ditions in a panel of three ESFT cell lines, which harbour
constitutively activated STAT3. As a STAT3 negative control
cell line, we used in our experiments the prostate cancer line
P C 3 ,w h i c hi sh o m o z y g o u sS T A T 3n u l l[ 16]. As a pharma-
cological inhibitor of STAT3, we used S3i-201, which has
been developed through structure-based virtual screening
and targets the STAT3 SH2-domain [14]. We found that at
100μmol/L (previously reported IC50 of 86 ± 33μmol/L)
S31-201 reduced viability of STAT3 positive ESFT tumour
cells, but not of the STAT3 null PC3 cell line. At higher drug
concentrations, cell viability was also diminished in the PC3
cell line, indicating STAT3-indepedent eﬀects of S3i-201 at
such concentrations. Our ﬁndings are consistent with data
presented in the original drug discovery paper of S3i-201.
Here Siddiquee et al. reported that in breast cancer cell lines
S3i-201 inhibited tumour growth, with an IC50 of 86 ±
33μmol/L and with STAT3-independent cytotoxic eﬀects at
higher drug concentrations [14]. Our observations therefore
lend support to the hypothesis that STAT3 plays a nonre-
dundant role in contributing to growth of ESFT cell lines.
ThehighIC50ofS3i-201almostcertainlydisqualiﬁesitfrom
being a clinically usable drug.
Next we studied the eﬀects of STAT3 inhibition on che-
mokine secretion patterns of ESFT cell lines through che-
mokine arrays performed on supernatants of ESFT cells. We
conﬁrmed STAT3 inhibition in the cells that produced the
supernatantsthroughWesternblotting,andweusedaSTAT3
null cell line PC3 to exclude nonspeciﬁc eﬀects. We found
changes in chemokine levels of known STAT3 targets such
as IL-8 whose secretion was increased by STAT3 inhibition
in all three ESFT cell lines, but not in PC3. In addition,Sarcoma 5
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Figure 3: STAT3 inhibition in ESFT cells alters the levels of a limited number of chemokines. Upper panel the gray up-pointing triangle
denotes an increase, and the black down-pointing triangle denotes a decrease, of more than 10%, observed in two independent experiments
for each cell line. The changes represent a ratio of density values, comparing arrays of STAT3-inihibited cells with arrays of DMSO-treated
cells. Lower panel examples of arrays performed on supernatants of STAT3 null control cells (PC3) and the ESFT cell line SKNMC, cultured
in the absence (DMSO treatment) or presence (S3i-201 treatment) of STAT3 inhibition. Cκβ8-1 = CCL23, ENA-78 = CXCL5, GRO = pan
marker for GRO family chemokines, GROα = CXCL1, IL-8 = CXCL8, IP-10 = CXCL10, MDC = CCL22, MIP-1β = CCL4, MIP-1δ = CCL15,
PARC = CCL18, and RANTES = CCL5.
STAT3 inhibition induced a distinct the pattern of changes in
chemokine secretion in each ESFT cell line. The signiﬁcance
of these ﬁndings is twofold. First, they suggest that STAT3
plays a role in regulating the chemokine environment of
ESFT cell lines. Second, our observations highlight that in
each ESFT cell lines STAT3 may be integrated into diﬀerent
immunological pathways.
5. Conclusion
In this study we conﬁrm the ﬁnding that a subset of ESFT
contains P-STAT3 positive tumour cells. Furthermore, we
describe two novel distribution patterns of PSTAT3 positive
tumourcells.Ourinvitroexperimentsprovideevidencethat,
in ESFT cell lines, STAT3 plays its classical role of contribut-
ing to tumour growth and regulating the tumour immune
environment. As global eﬀorts are underway to develop clin-
ically usable STAT3 inhibitors, our ﬁndings have to be vali-
dated in diﬀerent in vitro and in vivo models of ESFT, to pro-
vide a rationale for targeting STAT3 in patients suﬀering
from ESFT.
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